- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05775380
The Role of Pioglitazone in Vascular Transcriptional Remodeling (PREVALENT)
January 11, 2024 updated by: Andrei Carvalho Sposito, University of Campinas, Brazil
The Role of Pioglitazone in Vascular Transcriptional Remodeling in Individuals Undergoing Coronary Artery Bypass Grafting
Acute myocardial infarction (AMI) remains the leading cause of death worldwide.
In this scenario, early coronary reperfusion is the main therapeutic strategy as it substantially reduces mortality.
Paradoxically, however, reperfusion triggers additional tissue damage that accounts for about 50% of the infarcted heart mass, i.e., ischemia and reperfusion injury (IRL).
In this context, sphingosine-1-phosphate (S1P) is a sphingolipid synthesized by sphingosine kinases (Sphk), carried in plasma bound to high-density lipoprotein (HDL) and released after cellular damage such as LIR.
Particularly, in animal models of AMI, therapies targeting downstream S1P receptor signaling triggered by HDL/S1P are able to promote endothelial barrier functions and attenuate secondary damage to LIR.
Thus, the molecular control of sphingosine kinase 1 (Sphk1) transcription during LIR in vivo or during hypoxia/reoxygenation (H/R) in vitro may represent an important mechanism for maintaining endothelial homeostasis since it promotes the generation of S1P and this may promote subsequent HDL enrichment.
Thus, the role of pioglitazone hydrochloride 45mg/day for five days in volunteers undergoing coronary artery bypass grafting (BVR) will be investigated in order to verify the vascular expression of SPhk1, transcriptome and vascular proteome remodeling, as well as S1P content in HDL.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This will be a prospective, randomized and open clinical study.
From a sample of patients hospitalized for myocardial revascularization surgery, followed at the cardiac surgery outpatient clinic, 20 research participants, male, aged over 40 years, non-diabetic or diabetic with disease duration of less than 10 years, glycated hemoglobin <8% and non-user of NPH insulin, body mass index (BMI) between 20 and 34.9kg/m2 and glomerular filtration rate above 45mL/min who will be monitored at the Hospital de Clínicas/UNICAMP and randomized to receive pioglitazone hydrochloride 45mg/day for 5 days before surgery.
The amount of S1P in HDL at baseline (before surgery) will be assessed.
This same measurement will be repeated on day 5 (coinciding with the day of surgery) after using pioglitazone hydrochloride 45mg/day.
In addition, on the day of surgery, a saphenous vein fragment of approximately 2 cm and an internal thoracic artery fragment of approximately 1 cm will be collected, which will not impair the quality of the graft nor the extent of the material to be used as a graft, because in this case the vascular material is abundant.
An aortic artery button and an atrial appendage button will also be collected, which will be discarded.
In addition, the results of serum troponin levels in the first 24h post-SVR (6, 12, 24h) will be evaluated to estimate the extent of troponin release.
Postoperative examination.
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Andrei Sposito, Professor
- Phone Number: +551935218788
- Email: sposito@unicamp.br
Study Contact Backup
- Name: Isabella Bonilha, biomedical
- Phone Number: +551935217959
- Email: ibonilha@unicamp.br
Study Locations
-
-
SP
-
Campinas, SP, Brazil, 13083-887
- Recruiting
- University of Campinas
-
Principal Investigator:
- Andrei C Sposito, MD, PhD
-
Contact:
- Andrei C Sposito, MD, PhD
- Phone Number: +551935218788
- Email: sposito@unicamp.br
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male individuals
- Individuals undergoing CABG surgery for coronary artery disease
- Be over 40 years of age
- BMI between 20 and 34.9kg/m2
- Non-diabetic or if diabetic, disease duration < 10 years, Hba1c < 8%, non-user of NPH insulin
- Ejection fraction > 40%
- Glomerular filtration rate > 45 mL/min
Exclusion Criteria:
- BMI greater than 35 kg/m2, steatohepatitis, chronic kidney disease, systemic vasculitis, conditions that induce systemic inflammation such as psoriasis and systemic lupus erythematosus
- contraindications to the use of pioglitazone hydrochloride (heart failure, liver failure - AST or ALT > 2.5x upper normal limit, history of bladder cancer or macroscopic hematuria without investigation)
- moderate or severe valve disease
- need for concomitant use of other hypoglycemic therapies during hospitalization, particularly insulin
- peripheral edema
- recent hospitalization
- known allergy to any study drug
- polyuria, polydipsia, weight loss, or other clinical signs of volume depletion or diabetes, difficult-to-control systemic arterial hypertension, defined as individuals taking 4 or more drugs
- those who withdraw the Informed Consent Form (TCLE), or who, for some reason, are not able to sign or understand the TCLE
- history of gastrointestinal disorders that may interfere with study drug absorption
- research participant who is participating in other clinical trials or whose participation ended less than six months ago
- Research participant who has left ventricular dysfunction
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Pioglitazone
Research participants will be randomized to receive pioglitazone hydrochloride 45mg/day for 5 days prior to coronary artery bypass surgery.
|
We investigated the role of pioglitazone hydrochloride 45mg/day for five days in patients admitted for coronary artery bypass grafting (CABG) in order to investigate vascular SPhk1 expression, vascular transcriptome and proteome remodeling, as well as S1P content in HDL
Other Names:
|
No Intervention: Placebo
Research participants will be randomized to not receive intervention in the days prior to coronary artery bypass graft surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HDL-S1P change
Time Frame: Five days
|
Change in S1P content of isolated HDL between baseline and after treatment with pioglitazone hydrochloride 45 mg/day
|
Five days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SPHK1 - internal thoracic artery
Time Frame: Five days
|
Difference in SPHK1 expression in the internal thoracic artery cells determined by western blot between groups
|
Five days
|
S1PR1 - saphenous vein
Time Frame: Five days
|
Difference in S1P receptor (S1PR1) expression in saphenous vein endothelial cells determined by western blot between groups
|
Five days
|
SPHK1 - aortic artery
Time Frame: Five days
|
Difference in SPHK1 expression in the aortic artery cells determined by western blot between groups;
|
Five days
|
SPHK1 - atrial appendage
Time Frame: Five days
|
Difference in SPHK1 expression in the atrial appendage cells determined by western blot between groups;
|
Five days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Andrei Sposito, Professor, University of Campinas, Brazil
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 15, 2023
Primary Completion (Estimated)
June 28, 2024
Study Completion (Estimated)
December 22, 2024
Study Registration Dates
First Submitted
March 7, 2023
First Submitted That Met QC Criteria
March 17, 2023
First Posted (Actual)
March 20, 2023
Study Record Updates
Last Update Posted (Actual)
January 12, 2024
Last Update Submitted That Met QC Criteria
January 11, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PREVALENT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Reperfusion Injury
-
University of AarhusCompletedReperfusion Injuries, Myocardial
-
University of ChileFondo Nacional de Desarrollo Científico y Tecnológico, ChileCompletedReperfusion Injury | Acute Myocardial Infarction | Ischemia-reperfusion Injury | Reperfusion Injury, Myocardial | Reperfusion ArrhythmiasChile
-
Indonesia UniversityEnrolling by invitationReperfusion Injury, MyocardialIndonesia
-
Cukurova UniversityCompleted
-
Chinese PLA General HospitalUnknown
-
Clinical Hospital Center RijekaNot yet recruitingMyocardial Ischemic-reperfusion Injury
-
Chinese PLA General HospitalUnknownReperfusion Injury, Myocardial
-
Royal Brompton & Harefield NHS Foundation TrustRecruitingMyocardial Infarction | Reperfusion Injury, MyocardialUnited Kingdom
-
Shahid Beheshti University of Medical SciencesPooyesh DarouCompletedMyocardial Ischemic Reperfusion InjuryIran, Islamic Republic of
-
Beijing Friendship HospitalUnknownReperfusion Injury, Myocardial | STEMI - ST Elevation Myocardial InfarctionChina
Clinical Trials on Pioglitazone 45 mg
-
Mylan Pharmaceuticals IncCompleted
-
Mylan Pharmaceuticals IncCompleted
-
Dasman Diabetes InstituteKuwait University; Ministry of Health, Kuwait; Texas Diabetes InstituteUnknownCovid19 | Type 2 DiabetesQatar, Kuwait
-
The University of Texas Health Science Center at...Recruiting
-
Pennington Biomedical Research CenterRecruitingLung CancerUnited States
-
Albert Einstein College of MedicineTakedaCompletedType 2 Diabetes MellitusUnited States
-
University of Texas Southwestern Medical CenterRecruitingNephrolithiasis, Uric AcidUnited States
-
University of Texas Southwestern Medical CenterNational Institutes of Health (NIH)Completed
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 2United States, Estonia, Germany, Latvia, Spain, United Kingdom
-
Milton S. Hershey Medical CenterTerminatedHyperglycemia | Diabetes | Stroke, AcuteUnited States